ClinicalTrials.gg
Status unknownNCT05047666CLEARUpdated Sep 17, 2021

COVID-Like Illness Respiratory Pathogens. A Prospective Cohort on the COVID-19 Post-acute Condition

An observational study in Respiratory Infection, COVID-19 Respiratory Infection and Sequelae of; Infection, sponsored by Bernhard Nocht Institute for Tropical Medicine. Status unknown. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2021-09-17.

Sponsored by Bernhard Nocht Institute for Tropical Medicine · Observational

How we know

The sponsor has not verified this record recently (last verified Sep 2021), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,232
Ages
16 Years and older
Sex
All
01

Study summary

Identifying multiorgan sequalae and complications through high quality, prospective matched controlled studies throughout the course of COVID-19 is important for the acute and long-term management of patients and for health systems' planning. Further, it is key to understand the link between acute illness and long term consequences particularly in those already living with other comorbidities such as cardiovascular diseases or cancer.

Since the clinical presentation of COVID-19 can resemble a variety of common respiratory infections, describing the distribution of pathogens and the severity of clinical presentation associated with COVID-like illnesses (CLI) infections is important to generate a baseline clinical description by comparing potential long-term effects of PCR-confirmed COVID-19 to those following other respiratory infections.

To gain a better understanding of the clinical burden on COVID-19 survivors we will undertake a comparative evaluation within a cohort of PCR-confirmed individuals with COVID-19 vs. those PCR-confirmed symptomatic individuals with other respiratory pathogens plus healthy individuals from the community.

The results will inform strategies to prevent long term consequences; inform clinical management, interventional research, direct rehabilitation, and inform public health management to reduce overall morbidity and improve outcomes of COVID-19.

Read the detailed description

This is an observational prospective matched cohort study to evaluate the post-acute consequences of the SARS-CoV-2 symptomatic infection (case-positives) while having as comparison groups (1) symptomatic controls (case-negatives) and (2) healthy controls, that are healthy individuals recruited from the same community of the cases, but not arise from the same household. After pre-screening of COVID-19 symptoms at the hospital and other satellite health centers, consenting/assenting patients of 16 years of age and above with all range of PCR-confirmed Covid-19 disease severity -from mild to severely ill hospitalized patients- will be recruited and matched to other Non-SARS-CoV-2 PCR-determined patients and to healthy community controls. Then, they will be followed up for 12 months (13 months after screening) to determine the occurrence of admissions, any outpatient encounter, symptoms (new or persistent) and concomitant use of medication after 28 days of diagnosis.

At recruitment, respiratory samples are collected for respiratory infections diagnosis. Also, blood samples are collected to generate baseline data on potential biomarkers associated to occurrence of investigated outcomes. This will include biochemistry (including inflammatory markers) and hematology as well as SARS-CoV-2 serology (IgG) which will also be taken at the end of follow up to rule out infection during the course of the follow up. Though, the serology testing won't be done along each recruitment but in batches during the study period. Clinical (symptoms and diagnosis), socioeconomic, demographic, household conditions, health seeking behavior and medical history information will be gathered.

02

Conditions studied

  • Respiratory Infection
  • COVID-19 Respiratory Infection
  • Sequelae of; Infection
03

In context

Respiratory Tract Infections

753 studies on the registry are indexed under Respiratory Tract Infections; 112 are open to participants now.

This study's planned enrollment of 1,232 is above the median of 350 across 184 observational studies indexed under Respiratory Tract Infections.

Browse Respiratory Tract Infections studies →

Lead sponsor

Bernhard Nocht Institute for Tropical Medicine is the lead sponsor of 10 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

This study takes place in Assin Foso, Assin North District, Ghana. This is a semi rural area. Participants are recruited from the Saint Francis Xavier Hospital, the reference center of the region, when the seek for health services due to respiratory symptoms. Healthy controls are recruited from the communities from where cases arise.

Eligibility criteria

  1. For symptomatic patients attending to the SFXH or other satellite health centers

    • Inclusion Criteria

      1. Patients > or =16 years of age
      2. Presenting respiratory symptoms
      3. Positive respiratory sample for SARS-CoV-2 or other respiratory infections included in the panel
      4. Possibility to be contacted during follow-up
      5. Consented participation
      6. Patients which households are located within the study catchment area
    • Exclusion Criteria

      1. Symptomatic patients who test negative for all pathogens of the PCR-based respiratory panel.
      2. Symptomatic patients who test negative for the SARS-CoV-2 RDT and do not meet the matching criteria (age and residency (community)) as symptomatic controls to any of the recruited cases (to be considered as controls for the Antimicrobial Use Workpackage)
  2. Antimicrobial Use Work package (A subset of hospitalized, symptomatic patients are to be recruited as control group for the Antimicrobial Use Workpackage, if they meet the inclusion criteria)

    • Inclusion Criteria

      1. Patients > or =16 years of age
      2. Presenting respiratory symptoms
      3. Negative respiratory sample for SARS-CoV-2 (RDT)
      4. Do not meet the matching criteria (age and residency (community)) as symptomatic controls to any of the recruited cases
      5. Admitted to SFXH
      6. Consented participation
  3. For healthy controls from the community

    • Inclusion Criteria

      1. Patients > or =16 years of age
      2. Meet the age and residency (community) criteria to be matched to the cases
      3. Possibility to be contacted during follow-up
      4. Consented participation
    • Exclusion Criteria

      1. Presenting COVID-19 like symptoms
      2. Positive for SARS-CoV-2 RDT Eligible participants in the community presenting with an acute illness can be considered for inclusion as a case and recommended for referral to SFXH/ satellite health centre.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,232 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Cases Group

    Also called in our study 'Case-Positives'. These are those with respiratory symptoms suspected of COVID-19 that actually test positive (PCR).

  • Symptomatic Control Group

    Also called in our study 'Case-Negatives'. These are those with respiratory symptoms suspected of COVID-19 that actually test negative for SARS-CoV-2 but positive for any other pathogen included in our respiratory PCR-based panel.

  • Healthy Control Group

    At the community.

06

What researchers measure

Primary outcomes

  1. Admissions and Outpatient encounter

    Cumulated number of admissions and outpatient encounters within 13 months post PCR diagnosis

    Time frame: 13 months

  2. Persistent or new symptoms

    Cumulated number of persistent/new symptoms within 13 months post PCR diagnosis

    Time frame: 13 months

  3. Medication and therapy

    Cumulated therapy and use within 13 months post PCR diagnosis defined as: 1. Average weekly intake of particular medication(s) 2. Newly use of a particular medication(s)

    Time frame: 13 months

Secondary outcomes

  1. Patients' symptoms outcome

    Occurrence of sequalae, post-acute symptoms and long-term patients' outcomes

    Time frame: 13 months

  2. Pathogen detection

    Pathogens detected by PCR respiratory panel

    Time frame: 13 months

Other outcomes

  1. Exploratory Endpoint 1

    Viral variants detection via sequencing in the subgroup of symptomatic PCR-positive SARS-CoV-2 patients using the test-negative design.

    Time frame: 13 months

  2. Exploratory Endpoint 2

    Vaccine effectiveness in the subgroup of symptomatic PCR-positive SARS-CoV-2 patients using the test-negative design.

    Time frame: 13 months

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2021; primary completion for Oct 2022, 12 months later.

Of 67 non-industry observational studies under Respiratory Tract Infections, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 12 months is below that.

Counting every sponsor, half of 86 studies reached it within 18 months; a quarter within 8 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2021
First posted
Sep 17, 2021
StartEst.
Oct 2021
Primary completionEst.
Oct 2022
CompletionEst.
Mar 2023
Last update
Sep 17, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05047666
Lead sponsor
Bernhard Nocht Institute for Tropical Medicine
Collaborators
Kumasi Centre for Collaborative Research (KCCR)
Responsible party
Sponsor
First posted
Sep 17, 2021
Start date
Oct 2021 (estimated)
Primary completion
Oct 2022 (estimated)
Completion
Mar 2023 (estimated)
Last update
Sep 17, 2021

Study contacts

Ricardo Strauss, Dr. MD. MPH
Contact
ricardo.strauss@bnitm.de
+49 40 42818 243
Ricardo Strauss, Dr.MD. MPH
principal investigator · Bernhard Nocht Institute for Tropical Medicine
Jürgen May, Prof. Dr.
principal investigator · Bernhard Nocht Institute for Tropical Medicine
Oumou Maiga-Ascofare, PhD
principal investigator · Kumasi Center for Collaborative Research in Tropical Medicine
John Amuasi, MBChB, MPH, PhD
principal investigator · Kumasi Center for Collaborative Research in Tropical Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion